Background/aims: To assess LDL-apheresis efficacy to lower Lp(a) and to compare the effects of Usual Medical Care (UMC) a 12-months study was carried out. The incidence of new coronary artery disease (CAD) events/need of revascularization, was also monitored. Methods: Twenty-one patients with hyperLp(a)lipidemia and angiographically documented CAD were randomly assigned to LDL-apheresis every week, or the UMC. Results: LDL-apheresis group, averaged an Lp(a) reduction of 57.8 ± 9.5% vs. basal values (P < 0.001). In the UMC group Lp(a) increased in 1 year to 14.7 ± 36.5% (P = 0.66). Stepwise multivariate regression analysis for predictors of Lp(a) including: type of treatment, smoking, hypertension, age, age at first cardiovascular event, initial Lp(a), LDL, and BMI values, was performed. Only the type of treatment was co-related (P < 0.001): Lp(a) variation (beta) = 0.863. The model has R2 adjusted relative risk of 0.725. Conclusion: LDL-apheresis could be the first line treatment of isolated hyperLp(a)lipidemia when CAD is established. New CAD events/cardiac interventions were not observed. © 2009 Elsevier Ltd. All rights reserved.
Stefanutti, C., Vivenzio, A., Di Giacomo, S., Mazzarella, B., Ferraro, P. M., Abbolito, S., Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care, <<TRANSFUSION AND APHERESIS SCIENCE>>, 2010; 42 (1): 21-26. [doi:10.1016/j.transci.2009.10.003] [http://hdl.handle.net/10807/93226]
Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care
Di Giacomo, Salvatore;Ferraro, Pietro ManuelPenultimo
;
2010
Abstract
Background/aims: To assess LDL-apheresis efficacy to lower Lp(a) and to compare the effects of Usual Medical Care (UMC) a 12-months study was carried out. The incidence of new coronary artery disease (CAD) events/need of revascularization, was also monitored. Methods: Twenty-one patients with hyperLp(a)lipidemia and angiographically documented CAD were randomly assigned to LDL-apheresis every week, or the UMC. Results: LDL-apheresis group, averaged an Lp(a) reduction of 57.8 ± 9.5% vs. basal values (P < 0.001). In the UMC group Lp(a) increased in 1 year to 14.7 ± 36.5% (P = 0.66). Stepwise multivariate regression analysis for predictors of Lp(a) including: type of treatment, smoking, hypertension, age, age at first cardiovascular event, initial Lp(a), LDL, and BMI values, was performed. Only the type of treatment was co-related (P < 0.001): Lp(a) variation (beta) = 0.863. The model has R2 adjusted relative risk of 0.725. Conclusion: LDL-apheresis could be the first line treatment of isolated hyperLp(a)lipidemia when CAD is established. New CAD events/cardiac interventions were not observed. © 2009 Elsevier Ltd. All rights reserved.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
